<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00428506</url>
  </required_header>
  <id_info>
    <org_study_id>ALB-PPCD</org_study_id>
    <nct_id>NCT00428506</nct_id>
  </id_info>
  <brief_title>Albumin 4 gr/L vs 8 gr/L in the Prevention of Post-Paracentesis Circulatory Dysfunction</brief_title>
  <official_title>Albumin 4 gr/L vs 8 gr/L in the Prevention of Post-Paracentesis Circulatory Dysfunction in Cirrhotic Patients With Ascites</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Turin, Italy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Turin, Italy</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the infusion of albumin 4 gr per liter of
      ascites removed is as effective as the infusion of albumin 8 gr per liter of ascites removed
      in the prevention of post-paracentesis circulatory dysfunction
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Large-volume paracentesis associated with plasma volume expansion is the first-line treatment
      of tense ascites in cirrhotic patients. When paracentesis is performed without volume
      expansion, an high proportion of patients develop a complication named post-paracentesis
      circulatory dysfunction, which is characterized by a marked activation of the
      renin-angiotensin-aldosterone system. PPCD has been associated with renal impairment, rapid
      recurrence of ascites and shorter survival. Infusion of albumin is very effective in the
      prevention of PPCD, but has sever inherent drawbacks: the theoretical possibility of
      transmission of infectious diseases and the high costs. Other synthetic plasma volume
      expanders have been proposed in the last decades, but they are less effective than albumin
      when large (&gt; 5 L) volume paracentesis are performed. Albumin is conventionally given in a
      dosage of 8 gr per liter of ascites removed; however no information has yet been reported on
      the use of lower dosages of albumin in this context. This would be interesting, because of
      the obvious advantages in terms of costs reduction.

      The aim of the present study is to compare the efficacy of the infusion of albumin 4 gr vs 8
      gr per liter of ascites removed in the prevention of PPCD.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2007</start_date>
  <completion_date type="Anticipated">December 2008</completion_date>
  <primary_completion_date type="Anticipated">December 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>renin-angiotensin-aldosterone activation</measure>
    <time_frame>4-6 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>renal function</measure>
    <time_frame>4-6 days</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Tense Ascites in Cirrhosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>albumin 4 gr/L ascites removed</intervention_name>
    <description>albumin 4 gr/L ascites removed</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>albumin 8 gr/L ascites removed</intervention_name>
    <description>albumin 8 gr/L ascites removed</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cirrhosis and ascites submitted to paracentesis &gt; 5 liters

          -  Age: 18-75 years

          -  Informed written consent

        Exclusion Criteria:

          -  Multinodular HCC (&gt; 3 nodules)

          -  Portal vein thrombosis

          -  Ongoing bacterial infection

          -  Ongoing or recent (less than one week) bleeding

          -  Cardio-pulmonary failure

          -  Hepatorenal syndrome type 1

          -  Severe coagulopathy: platelets &lt; 30.000/mm3 and/or PT &lt; 30%

          -  Ongoing treatment with vasoactive drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mario Rizzetto, MD</last_name>
    <role>Study Director</role>
    <affiliation>Division of Gastroenterology and Hepatology, San Giovanni Battista Hospital, Turin, Italy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carlo Alessandria, MD</last_name>
    <phone>+390116335561</phone>
    <email>carloalessandria@libero.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>San Giovanni Battista Hospital</name>
      <address>
        <city>Turin</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlo Alessandria, MD</last_name>
      <phone>+3901163335561</phone>
      <email>carloalessandria@libero.it</email>
    </contact>
    <investigator>
      <last_name>Alfredo Marzano, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Sola-Vera J, Miñana J, Ricart E, Planella M, González B, Torras X, Rodríguez J, Such J, Pascual S, Soriano G, Pérez-Mateo M, Guarner C. Randomized trial comparing albumin and saline in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients with ascites. Hepatology. 2003 May;37(5):1147-53.</citation>
    <PMID>12717396</PMID>
  </reference>
  <reference>
    <citation>Ginès A, Fernández-Esparrach G, Monescillo A, Vila C, Domènech E, Abecasis R, Angeli P, Ruiz-Del-Arbol L, Planas R, Solà R, Ginès P, Terg R, Inglada L, Vaqué P, Salerno F, Vargas V, Clemente G, Quer JC, Jiménez W, Arroyo V, Rodés J. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology. 1996 Oct;111(4):1002-10.</citation>
    <PMID>8831595</PMID>
  </reference>
  <verification_date>April 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2007</study_first_submitted>
  <study_first_submitted_qc>January 29, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2007</study_first_posted>
  <last_update_submitted>April 9, 2008</last_update_submitted>
  <last_update_submitted_qc>April 9, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 11, 2008</last_update_posted>
  <responsible_party>
    <name_title>University of Turin</name_title>
    <organization>Mario Rizzetto</organization>
  </responsible_party>
  <keyword>ascites</keyword>
  <keyword>cirrhosis</keyword>
  <keyword>post-paracentesis circulatory dysfunction</keyword>
  <keyword>albumin</keyword>
  <keyword>portal-hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Ascites</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

